Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
NCT ID: NCT04862286
Last Updated: 2025-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
132 participants
INTERVENTIONAL
2021-07-24
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). A maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide.
Participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are followed up for safety for 20 weeks after last dose.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
NCT04713592
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
NCT04435600
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
NCT03047395
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
NCT03875482
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
NCT02672852
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risankizumab
Participants will receive risankizumab subcutaneous (SC) injection every 12 weeks for 204 weeks.
Risankizumab
Subcutaneous (SC) injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risankizumab
Subcutaneous (SC) injection.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
6 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB Department of Dermatology /ID# 252305
Birmingham, Alabama, United States
First OC Dermatology /ID# 226942
Fountain Valley, California, United States
Integrative Skin Science and Research /ID# 226108
Sacramento, California, United States
University of California San Diego - Rady Children's Hospital San Diego /ID# 252348
San Diego, California, United States
Solutions Through Adv Rch /ID# 226104
Jacksonville, Florida, United States
Olympian Clinical Research- St. Petersburg /ID# 226106
St. Petersburg, Florida, United States
Advanced Clinical Research Institute /ID# 248827
Tampa, Florida, United States
University Dermatology and Vein Clinic, LLC /ID# 226100
Darien, Illinois, United States
Arlington Dermatology /ID# 226097
Rolling Meadows, Illinois, United States
Skin Cancer and Dermatology Institute - Reno /ID# 248828
Reno, Nevada, United States
Univ Hosp Cleveland /ID# 248825
Cleveland, Ohio, United States
Apex Clinical Research Center /ID# 248830
Mayfield Heights, Ohio, United States
Medical University of South Carolina /ID# 248831
Charleston, South Carolina, United States
West Virginia University Hospitals /ID# 263438
Morgantown, West Virginia, United States
Wisconsin Medical Center /ID# 263437
Milwaukee, Wisconsin, United States
Karma Clinical Trials /ID# 233985
St. John's, Newfoundland and Labrador, Canada
Hospital for Sick Children /ID# 233986
Toronto, Ontario, Canada
Fachklinik Bad Bentheim /ID# 243904
Bad Bentheim, Lower Saxony, Germany
Universitaetsklinikum Bonn /ID# 243910
Bonn, North Rhine-Westphalia, Germany
Universitaetsklinikum Muenster /ID# 243905
Münster, North Rhine-Westphalia, Germany
Universitaetsmedizin Mainz /ID# 243907
Mainz, Rhineland-Palatinate, Germany
Universitaetsklinikum Carl Gustav Carus Dresden /ID# 243908
Dresden, Saxony, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 243883
Kiel, Schleswig-Holstein, Germany
Nagoya City University Hospital /ID# 248429
Nagoya, Aichi-ken, Japan
Mie University Hospital /ID# 263008
Tsu, Mie-ken, Japan
Kansai Medical University Hirakata Hospital /ID# 252332
Hirakata-shi, Osaka, Japan
Tokyo Medical University Hospital /ID# 252331
Shinjuku-ku, Tokyo, Japan
High-Med Przychodnia Specjalistyczna /ID# 243846
Warsaw, Masovian Voivodeship, Poland
Uniwersytecki Szpital Kliniczny im. F. Chopina w Rzeszowie /ID# 243850
Rzeszów, Podkarpackie Voivodeship, Poland
Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 243849
Gdansk, Pomeranian Voivodeship, Poland
Dermed Centrum Medyczne Sp. z o.o /ID# 243847
Lodz, Łódź Voivodeship, Poland
Dermoklinika Medical Center /ID# 243848
Lodz, Łódź Voivodeship, Poland
Hospital Sant Joan de Deu /ID# 241103
Esplugues de Llobregat, Barcelona, Spain
Hospital General Universitario Gregorio Maranon /ID# 241099
Madrid, , Spain
Hospital Universitario Infanta Leonor /ID# 241100
Madrid, , Spain
Hospital Universitario 12 de Octubre /ID# 241102
Madrid, , Spain
Complejo Hospitalario Universitario de Pontevedra /ID# 241101
Pontevedra, , Spain
Royal Devon & Exeter Hospital /ID# 245101
Exeter, Devon, United Kingdom
Derriford Hospital and the Royal Eye Infirmary /ID# 245104
Plymouth, Devon, United Kingdom
Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 245100
London, Greater London, United Kingdom
Chelsea and Westminster Hospital /ID# 245102
London, Greater London, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-500408-22-00
Identifier Type: OTHER
Identifier Source: secondary_id
M19-973
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.